Numbers are irrelevant. Ofirmev sells will go up and up till reach "saturation" point, like 50% + of all acute pain IV meds. We are way far from saturation point, and still waiting for Canada sales. Providing Management doesn't make some wrong move Cadence is long term hold winner. I am in.